Every material Form 8-K BriaCell Therapeutics Corp. has filed with the SEC since March 31, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
BriaPro Therapeutics, a subsidiary of BriaCell Therapeutics, filed unaudited financial statements for the three and nine months ended April 30, 2026, with Canadian regulators. The nine-month net loss rose to $712,236 from $519,804 a year earlier, and the filing states a material uncertainty about the company's ability to continue as a going concern, with BriaCell as its only stated financing source until it raises more capital.
Nine-month net loss of $712,236 versus $519,804 for the same period a year earlier; three-month net loss narrowed to $240,005 from $286,619
Cash of $299,950 at April 30, 2026, including a $300,000 related-party advance from BriaCell; negative working capital of $1,937,495
Amounts owed to BriaCell group companies totaled $2,093,345; the monthly service fee was reduced from $20,000 to $5,000 effective April 30, 2026
On March 31, 2026, the company acquired the sCD80 license from BriaCell for 23,972,589 common shares valued at $846,532
BriaCell Therapeutics agreed on May 31, 2026 to sell 1,449,300 common shares at $3.25 per share in a best-efforts offering through placement agent ThinkEquity, with the offering closing on June 2, 2026. The Company received gross proceeds of $4.71 million before placement agent fees and expenses, and says it will use the net proceeds for working capital, general corporate purposes and business objectives. The sale adds new shares outstanding, and the placement agent also received warrants, so existing shareholders' ownership may be diluted.
1,449,300 common shares sold at $3.25 per share; gross proceeds of $4.71 million per the 8-K, or about $4.7 million per the press releases
Placement agent received a cash fee of 7.5% of gross proceeds and warrants to buy 72,465 common shares at $4.0625, exercisable upon issuance and expiring five years from the May 31, 2026 agreement date
Offering was made under a Form S-3 shelf registration (File No. 333-276650) declared effective January 31, 2024
The 8-K states the offering closed on June 2, 2025 in one place; the June 2, 2026 closing press release and the filing's signature date indicate 2026
BriaCell Therapeutics filed interim financial statements for its subsidiary BriaPro Therapeutics for the three and six months ended January 31, 2026, showing larger losses than a year earlier and a shareholders' deficit of $1,618,141. The filing states there is a material uncertainty about BriaPro's ability to continue as a going concern, and that it depends entirely on BriaCell for funding until it raises additional financing.
Six-month net loss was $472,231, compared with $233,185 in the prior-year period; three-month net loss was $227,493, compared with $151,062.
Six-month research and development expenses were $433,307, compared with $130,023 a year earlier.
Amounts due to related parties were $1,606,112 at January 31, 2026, and cash and cash equivalents were $1.
On February 18, 2026, BriaPro agreed to acquire BriaCell's license to Soluble CD80; the transaction closed March 30, 2026, with 23,972,589 shares issued to BriaCell and a credit facility of up to $3,000,000.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every BriaCell Therapeutics Corp. filing is on SEC EDGAR ↗. 8-K briefs of other companies →